GeoVax Labs (GOVXW) News Today → HUGE BUY ALERT: Move Fast, Musk... (From Stansberry Research) (Ad) Free GOVXW Stock Alerts $0.03 0.00 (-13.14%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | finance.yahoo.comGeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024April 4, 2024 | finance.yahoo.comGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineMarch 28, 2024 | finance.yahoo.comGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressFebruary 13, 2024 | finance.yahoo.comGeoVax Announces Multiple Patent Issuances and AllowancesFebruary 6, 2024 | finance.yahoo.comGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterJanuary 31, 2024 | marketbeat.comTrading was temporarily halted for "GOVXW" at 07:01 PM with a stated reason of "News pending."January 29, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | markets.businessinsider.comEQS-News: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | finance.yahoo.comGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 4, 2024 | finance.yahoo.comGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsDecember 27, 2023 | finance.yahoo.comGeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024December 19, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxDecember 19, 2023 | finance.yahoo.comGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxNovember 14, 2023 | finance.yahoo.comProgress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023November 8, 2023 | finance.yahoo.comGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 30, 2023 | finance.yahoo.comGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineOctober 25, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming November Investor and Industry EventsOctober 9, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for Marburg Vaccine PatentOctober 5, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for HIV Vaccine PatentSeptember 26, 2023 | finance.yahoo.comGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentSeptember 20, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceAugust 29, 2023 | finance.yahoo.comGeoVax to Present at the Emerging Growth Conference on September 6, 2023August 10, 2023 | finance.yahoo.comGeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaAugust 9, 2023 | finance.yahoo.comGeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateJuly 24, 2023 | marketwatch.comGeoVax Labs Shares Rise 8% After Patent for Ebola VaccineJuly 11, 2023 | finance.yahoo.comGOVX - GeoVax Labs, Inc.July 10, 2023 | finance.yahoo.comGeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer ConferenceMay 24, 2023 | finance.yahoo.comGeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised PatientsMay 9, 2023 | finance.yahoo.comGeoVax Labs to Participate in A.G.P.’s Virtual Healthcare ConferenceMay 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Selecta Biosciences (SELB) and Assembly Biosciences (ASMB)April 26, 2023 | finance.yahoo.comGeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised HostApril 25, 2023 | finance.yahoo.comGeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023April 6, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine CandidateMarch 27, 2023 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Reports 2022 Year-End Financial Results and Provides Corporate UpdateFebruary 8, 2023 | finance.yahoo.comGeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based VaccinesNovember 9, 2022 | finance.yahoo.comGeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate UpdateOctober 26, 2022 | finance.yahoo.comGeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022October 11, 2022 | finance.yahoo.comGeoVax to Present at Vaccines Summit-2022August 10, 2022 | seekingalpha.comGeoVax: Possible Vaccine Advancements In 2 Big IndicationsAugust 3, 2022 | seekingalpha.comGeoVax Labs, Inc. (GOVX) CEO David A. Dodd on Q2 2022 Results - Earnings Call TranscriptAugust 3, 2022 | finance.yahoo.comGeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate UpdateJuly 30, 2022 | marketwatch.comGeoVax Labs Shares Rise 13% After Positive Study Results for Ebolavirus VaccineJuly 27, 2022 | marketwatch.comGeoVax Labs Gains Another 47% Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVXW and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE BUY ALERT: Move Fast, Musk... (Ad)I recently traveled to Phoenix, Arizona...And based on what I saw out there, I'm prepared to put my reputation on the line. Since 2018, my investment recommendations have averaged 115% per year. But one investment I've just discovered could blow them all away. You won't believe what I saw in Phoenix. GOVXW Media Mentions By Week GOVXW Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GOVXW News Sentiment▼0.260.57▲Average Medical News Sentiment GOVXW News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GOVXW Articles This Week▼10▲GOVXW Articles Average Week Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVXW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alpha Tau Medical News Today Artelo Biosciences News Today BriaCell Therapeutics News Today eFFECTOR Therapeutics News Today Fortress Biotech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GOVXW) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
